The pathophysiological link between avelumab and MFS remains incompletely defined but likely involves loss of peripheral tolerance and T-cell-mediated autoimmunity triggered by PD-L1 blockade [1,8-10]. The gene discussed is CD274; the disease is Marfan syndrome.